- Home
- GHG vs TRVI Comparison
GHG vs TRVI Comparison
Compare GHG & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- TRVI
- Stock Information
- Founded
- GHG 2004
- TRVI 2011
- Country
- GHG China
- TRVI United States
- Employees
- GHG N/A
- TRVI N/A
- Industry
- GHG Hotels/Resorts
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- TRVI Health Care
- Exchange
- GHG Nasdaq
- TRVI Nasdaq
- Market Cap
- GHG 259.8M
- TRVI 211.4M
- IPO Year
- GHG 2018
- TRVI 2019
- Fundamental
- Price
- GHG $2.56
- TRVI $4.12
- Analyst Decision
- GHG
- TRVI Strong Buy
- Analyst Count
- GHG 0
- TRVI 8
- Target Price
- GHG N/A
- TRVI $9.31
- AVG Volume (30 Days)
- GHG 14.7K
- TRVI 4.3M
- Earning Date
- GHG 02-25-2025
- TRVI 11-06-2024
- Dividend Yield
- GHG 3.91%
- TRVI N/A
- EPS Growth
- GHG N/A
- TRVI N/A
- EPS
- GHG 0.28
- TRVI N/A
- Revenue
- GHG $201,166,731.00
- TRVI N/A
- Revenue This Year
- GHG N/A
- TRVI N/A
- Revenue Next Year
- GHG $8.78
- TRVI N/A
- P/E Ratio
- GHG $9.21
- TRVI N/A
- Revenue Growth
- GHG N/A
- TRVI N/A
- 52 Week Low
- GHG $2.31
- TRVI $1.27
- 52 Week High
- GHG $3.69
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- GHG 46.30
- TRVI 62.71
- Support Level
- GHG $2.40
- TRVI $3.96
- Resistance Level
- GHG $2.57
- TRVI $4.48
- Average True Range (ATR)
- GHG 0.10
- TRVI 0.41
- MACD
- GHG 0.01
- TRVI 0.03
- Stochastic Oscillator
- GHG 50.72
- TRVI 76.03
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.